Imugene Receives Substantial Capital Injection; Extends Cash Runway to End of 2025 in Support of Ongoing Trials
Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue
Imugene to Receive A$11 Million R&D Tax Refund for FY23 | ASX:IMU, OTC:IUGNF
6 ASX Shares Down 50%+ in 2024. Are They Cheap?
Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial
Five at Five AU: ASX to End Week on a High Note | ASX:IMU, OTC:IUGNF
Why Imugene, Neuren, Sigma, and Smartgroup Shares Are Charging Higher
Imugene Opens First Australian Site for Azer-cel Clinical Trial Targeting Lymphoma | ASX:IMU, OTC:IUGNF
Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources Shares Are Charging Higher
Guess Which ASX 300 Stock Is Jumping 11% on Big News
Imugene VAXINIA Achieves Complete Response in Patient Two Years After Bile Tract Cancer Treatment
Imugene VAXINIA Achieves Complete Response in Patient Two Years After Bile Tract Cancer Treatment | ASX:IMU, OTC:IUGNF
2 All Ords ASX Healthcare Shares Making BIG Moves on Quarterly Updates
Why AGL, Imugene, Star, and Woolworths Shares Are Dropping Today
Those Who Invested in Imugene (ASX:IMU) Five Years Ago Are up 144%
With Inflation 'Proving Persistent', Is Now Really a Good Time to Buy ASX Tech Shares?
AU Evening Wrap | ASX Surpasses 8200 as Fed Cuts Rates; BHP Rallies on Morgan Stanley Buy Rating
AU Evening Wrap | ASX Hits Record High Despite Slump in Rio Tinto and BHP
Imugene Secures FDA Orphan Drug Designation for Bile Tract Cancer Treatment
Imugene Price Target Cut 33% to A$0.10/Share by Bell Potter
No Data